Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
- Citation:
- Taha, A. M., M. M. Aboulwafa, H.Zedan, and O. M. Helmy,
"Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.",
Scientific Reports, vol. 12:, pp. 17889, 2022.
